Director and Head of Strategic Partnerships Saiid Zarrabian departs Kintara; receives $213,750 severance

TuHURA Biosciences, Inc./NV

Zarrabian steps down from Board and Head of Strategic Partnerships effective May 23, 2022 by mutual agreement, not due to disagreements.
Severance includes nine months base salary totaling $213,750 paid in installments, plus $24,826.67 one-time bonus.
Stock options accelerated: 2,517,713 vested (including 6 months service credit); 754,188 unvested options forfeited.
Healthcare and life insurance premiums reimbursed for up to nine months; non-solicitation covenant applies for 12 months.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Saiid Zarrabian

Head of Strategic Partnerships and Director

HURA · TuHURA Biosciences, Inc./NV

Effective: 2022-05-23
Filed: May 24, 2022, 7:59 PM ET

On May 20, 2022, Kintara Therapeutics, Inc. (the “Company”) and Saiid Zarrabian, the Company’s Head of Strategic Partnerships and a member of the Board of Directors (the “Board”) of the Company, mutually agreed that Mr. Zarrabian would step down from his role as Head of Strategic Partnerships and as a member of the Board, effective as of May 23, 2022 (the “Separation Date”) to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Saiid Zarrabian departed as Head of Strategic Partnerships and Director at TuHURA Biosciences, Inc./NV.

Action: stepped down
Role: Head of Strategic Partnerships and Director

Exact text from the filing

On May 20, 2022, Kintara Therapeutics, Inc. (the “Company”) and Saiid Zarrabian, the Company’s Head of Strategic Partnerships and a member of the Board of Directors (the “Board”) of the Company, mutually agreed that Mr. Zarrabian would step down from his role as Head of Strategic Partnerships and as a member of the Board, effective as of May 23, 2022 (the “Separation Date”) to pursue other opportunities.

View on SEC.gov

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-22-010535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.